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Abstract
Background: The tumor-associated glycoprotein osteopontin (OPN) is discussed as a plasma
surrogate marker of tumor hypoxia and as an indicator of the presence of pleural mesothelioma in
asbestos-exposed individuals. The clinical introduction of plasma OPN measurements requires the
availability of a reliable enzyme-linked immunosorbence assay (ELISA).
Methods: We compared previously described and currently available ELISA systems on 88 archival
plasma samples obtained from patients with head and neck or cervix cancer between 20 days
before and 171 after the start of radiotherapy.
Results: Median (range) plasma OPN levels were 667 (148.8–2095) ng/ml and 9.8 (3.5–189.5) ng/
ml for a previously described and a newly marketed assay, respectively. Although results for
different assays were significantly correlated (r = 0.38, p < 0.05, Spearman rank test), between-
assay factors ranged from 2.0 to 217.9 (median 74.6) in individual patients. OPN levels in cervix
cancer patients were comparable to those of head and neck cancer patients.
Conclusion: Commercially available OPN ELISA systems produce different absolute plasma OPN
levels, compromising a comparison of individual patient data with published results. However,
different assays appear to have a similar capacity to rank patients according to plasma OPN level.
A review of literature data suggests that plasma OPN levels measured even with identical ELISA
systems can only be compared with caution.
Background
Recent publications have renewed interest in the measure-
ment of OPN, a tumor-associated glycoprotein secreted
into bodily fluids, in the plasma of tumor patients.
Plasma OPN level was shown by Le et al. to correspond
with Eppendorf electrode measurements of tumor oxy-
genation in patients with head and neck cancer [1], sug-
gesting a role for OPN as an endogenous marker of tumor
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hypoxia. In a landmark study, Overgaard et al. showed
that only patients with high plasma levels of OPN (upper
tertile) significantly benefitted from the addition of
nimorazole, a hypoxic radiosensitizer, compared to stand-
ard radiotherapy in patients with head and neck cancer
[2]. OPN may therefore serve as a marker by which to
select head and neck cancer patients for intensified,
hypoxia-specific, treatment. It is currently unclear whether
OPN may be similarly useful to predict tumor hypoxia in
other entities in which oxygenation also has prognostic
impact such as cervix cancer [3,4]. Additional interest in
OPN was raised by a prominent publication showing that
in individuals with asbestos exposure, serum OPN levels
can distinguish between those without cancer and those
with pleural mesothelioma [5]. A molecular mechanism
for the intracellular accumulation of OPN under hypoxia
has recently been described [6,7], although secretion of
OPN may require additional steps [8,9].
A widespread application of OPN measurement in patient
plasma or serum is dependent on the availability of relia-
ble commercial enzyme-linked immunosorbent assay
(ELISA) systems and may be affected by the problem of
comparability between results of different assay systems.
The choice of material, e. g. plasma vs. serum, and dura-
tion of storage may also affect the results of the ELISA.
To the authors' knowledge, the ELISA system utilized in
the two reports on plasma OPN as a marker of tumor
hypoxia in head and neck cancer [1,2], is no longer com-
mercially available We therefore performed a comparative
analysis, using different commercial ELISA systems, of
plasma OPN levels in 88 archival samples obtained from
patients with head and neck cancer or cervix cancer at dif-
ferent timepoints before, during or after radiotherapy.
Data were compared to published results for cancer and
non-cancer patients as well as normal controls obtained
with these ELISA systems.
Methods
Eighty-eight archival citrate plasma samples obtained
from patients treated with radiotherapy between Decem-
ber of 1998 and May of 2000 at the Martin Luther Univer-
sity of Halle, Germany, and stored at -80°C, were now
analyzed. Of these, 34 samples were from eleven patients
with head and neck cancer (ten males, one female) and 54
were from 12 patients with cervix cancer. The median
number of samples per patient was 4 (range 1 to 7). In
head and neck cancer patients, a median of 2 samples
(range 1 to 7) and in cervix cancer a median of 5.5 (range
1 to 7) samples were available. Samples were collected
between 20 days before and 171 days after initiation of
radiotherapy. Plasma sample collection was performed
after written informed consent and approved by the local
ethics committee
Plasma samples were analyzed in triplicate with different
commercial ELISA systems, according to the respective
manufacturers' instructions, as follows. Aliquots of all
samples were analyzed with the currently available Tit-
erZyme ELISA kit (Assay Designs, Ann Arbor, MI) intro-
duced in July of 2005 by this manufacturer ("assay A").
Aliquots of all cervix cancer samples were additionally
analyzed with the ELISA system previously marketed by
this manufacturer under the same name which was used
in previous publications on OPN as an endogenous
hypoxia marker [1,2]. This older version of the TiterZyme
assay was designated "assay B1". According to this manu-
facturer, this assay (old TiterZyme, B1) was supplied by a
third party producer (IBL, Gunma, Japan) who still mar-
kets this assay. All head and neck cancer samples were
additionally analyzed with the current IBL assay which
should be identical with the old TiterZyme assay and was
therefore designated "assay B2". In summary, each sample
was measured with one newly introduced ELISA assay (A)
and one older assay (B) marketed under two different
names (B1 and B2).
For each sample and assay, the mean of the triplicate
measurement was calculated. The factor of the difference
between assay B and assay A was determined for each sam-
ple. The correlation of results obtained with the newer
assay (A) and the older assay (B) was analyzed by calcula-
tion of the Spearman-rank correlation coefficient (p <
0.05 regarded as significant).
Results
The plasma OPN levels determined with assay A and assay
B are displayed for the overall group and separately for
patients with cervix cancer and head and neck cancer,
respectively, in Table 1. In the overall set of samples,
results obtained with assay A, the newly introduced assay,
were consistently much lower than those obtained with
assay B, the one frequently used in published reports. The
median and mean factors by which the results of the two
assays varied in individual patients were 77.1 and 74.6,
with a range between 2.0 and 217.9. The results obtained
with assay A and B were significantly correlated, as shown
in Fig. 1 (r = 0.37, p < 0.05). The two versions of assay B
marketed by different companies (B1 used in cervix and
B2 used in head and neck cancer samples), although not
compared against each other in identical samples, pro-
duced similar results in comparison with assay A (median
factor of 70.3 for B1 in cervix and of 76.5 for B2 in head
and neck), confirming that B1 and B2 can be regarded as
identical.
Although the time points at which samples were taken
were not necessarily comparable between cervix and head
and neck cancer patients, both assays indicated similar
plasma OPN levels in these two tumor entities withBMC Cancer 2006, 6:207 http://www.biomedcentral.com/1471-2407/6/207
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median OPN levels (head and neck vs. cervix) of 10.4 vs.
9.5 ng/ml (assay A) and 650.2 vs 667.0 ng/ml (assay B).
Discussion
OPN has been studied as a blood tumor marker since the
mid-1990. Its expression level has been linked to the pres-
ence or extent of metastases or to clinical progression in
several tumor entitities including breast, prostate and lung
cancer [review in [10]]. Most of the earlier studies were
performed with individually developed ELISA systems
preventing comparison of results between centers.
OPN has recently received renewed interest as a surrogate
marker of tumor hypoxia in head and neck cancer, a dis-
ease entity in which oxygenation is of prognostic impor-
tance [11]. The association of plasma OPN levels with
tumor oxygenation in head and neck cancer patients [1],
their association with prognosis after radiotherapy and
the benefit from a hypoxia-specific additional treatment
(nimorazole) only in patients with high OPN levels [2]
suggested that plasma OPN may in fact be a clinically use-
ful surrogate marker of tumor oxygenation. These interest-
ing results are a motivation to measure plasma OPN
prospectively in future clinical trials of treatments targeted
at hypoxic tumor cells or retrospectively in stored plasma
samples from other relevant patient groups and compare
the results to plasma OPN levels reported for head and
neck cancer patients. However, the ELISA assay kit (Tit-
erZyme by Assay Designs) used in the reports on plasma
OPN in head and neck cancer [1,2] was recently replaced
by a different assay marketed under the same name.
According to information from this manufacturer, the
older assay is still marketed by a different company (IBL).
In published reports on plasma OPN, both older assays
(Assay Designs old and IBL), which should yield identical
results, have been used (Table 2) but so far no results have
been published for the new Assay Designs ELISA system to
the authors' knowledge.
We therefore compared these different ELISA systems on a
set of 88 archival plasma samples from patients treated
with radiotherapy for head and neck or cervix cancer. The
main finding was that the OPN levels determined with the
new assay were much lower – by a mean factor of 77 –
than measured with either form of the older assay. There
was no uniform factor between old and new assay that
would permit calculation of one from the other. In indi-
vidual samples the factor ranged from 2 to 218. Neverthe-
less, OPN levels determined with the older and the newer
Osteopontin levels in individual plasma samples obtained  from cervix or head and neck cancer patients undergoing  radiotherapy Figure 1
Osteopontin levels in individual plasma samples obtained 
from cervix or head and neck cancer patients undergoing 
radiotherapy. All samples were measured with two different 
ELISA systems, a newly introduced assay (A) and an older 
assay (B) marketed under two different names (see text). 
The results of both assays were significantly correlated (p < 
0.05, Spearman rank test). For clarity, two data points with 
values of 80.5 and 189.5 ng/ml for assay A are not displayed.
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Table 1: Plasma osteopontin levels in head and neck cancer and cervix cancer patients as measured using two different ELISA 
systems.
patient group assay A assay B individual factors (assay B/A)
osteopontin (ng/ml) osteopontin (ng/ml)
all samples  mean ± SD 13.9 ± 21.0 786.0 ± 442.5 77.1 ± 41.4
(n = 88) median (range) 9.8 (3.5–189.5) 667.0 (148.8–2095.0) 74.6 (2.0–217.9)
head and neck cancer mean ± SD 16.1 ± 31.1 794.3 ± 467.2 76.3 ± 38.9
 (n = 34) median (range) 10.4 (3.8–189.5) 650.2 (148.8–1841.0) 76.5 (5.7–184.5)
cervix cancer mean ± SD 12.4 ± 11.0 780.7 ± 430.6 77.6 ± 43.3
 (n = 54) median (range) 9.5 (3.5–80.5) 667.0 (155.5–2095.0) 70.3 (2.0–217.9)BMC Cancer 2006, 6:207 http://www.biomedcentral.com/1471-2407/6/207
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assay were significantly correlated, suggesting that both
assays should have a similar potential for selection of
patients with poor-prognosis, hypoxic tumors. The fact
that both forms of the older assay had similar mean fac-
tors compared to the new assay supports equivalence of
the two. The large difference between old and new assay is
well explained by differences in the epitope recognition
sites of the respective capture antibodies provided with
the ELISA assay kits and is, at least in part, anticipated by
the range of standards provided with the respective kits
(5–320 vs. 2–32 ng/ml). Various molecular forms of OPN
have been described, resulting from RNA splicing, glyco-
sylation, phosphorylation and proteolytic fragmentation,
e. g. by thrombin [12]. The use of various combinations of
antibodies raised against four different portions of human
OPN in a total of six separate ELISA systems has been
shown to recognize distinct truncated or glycosylated
forms of OPN [13].
A review of published data for the two forms of the old
assay reveals that mean plasma OPN levels for healthy
volunteers, for instance, vary substantially even when the
identical ELISA kit is used (Table 2). This may in part be
explained by the different type of material analyzed, such
as EDTA plasma vs. citrate plasma vs. heparin plasma.
Some authors did not specify the type of plasma obtained
for OPN detection or analyzed serum samples, which
apparently results in lower levels of OPN in healthy vol-
unteers (Table 2). Conditions and duration of storage
may also be critical. As highlighted by the literature
review, many common non-malignant conditions,
including coronary artery disease, interstitial pneumonia
and other benign pulmonary diseases, multiple sclerosis
or liver dysfunction may cause elevated plasma OPN val-
ues [14-17]. Some of these conditions may be present to a
varying degree in groups of "healthy" volunteers, depend-
ing also on the age group selected.
Conclusion
As a consequence of the present results, the plasma OPN
levels obtained with commercially available ELISA assay
kits must be interpreted with caution. Differently opti-
mized kits may be marketed under the same name such
that comparison with published results may be compro-
mised. It appears that even despite the use of the identical
ELISA system, OPN levels are not reproducible in compa-
rable patient cohorts between laboratories. For instance,
the median values for untreated patients with advanced
head and neck cancer were 450 ng/ml and 113 ng/ml in
the two previously published series [1,2]. However, ele-
vated plasma OPN levels were consistently reported for
different groups of cancer patients compared to controls,
Table 2: Overview of osteopontin levels measured with commercially available ELISA systems in healthy controls, malignant and 
benign diseases.
assay material patient group (n) osteopontin mean 
± SD (ng/ml)
osteopontin 
median (range) 
(ng/ml)
ref.
Assay Designs (B1) citrate plasma head and neck cancer (54) von Hippel Lindau 
disease (31) healthy controls (15)
447 (261–843) 318 
(233–461)
450 [1]
plasma head and neck cancer (320) -- 113 (12–1382) [2]
plasma nasopharyngeal cancer healthy controls 184.6 (6.8–856.9)
75.9 (10–455)
--
--
[18]
EDTA plasma multiple sclerosis – relapsing patients (30)
healthy controls (10)
--
--
280
174
[17]
serum ovarian cancer (51)
healthy controls (28)
49
11
--
--
[19]
IBL (B2) serum pleural mesothelioma (76)
asbestos-related non-malignant disease (69)
healthy controls (45)
133 ± 10
30 ± 3
20 ± 4
--
--
--
[5]
EDTA plasma esophageal carcinoma (103) -- 606 (82.8–1980) [20]
plasma ovarian cancer (51)
healthy controls (107)
486.5
147.1
--
--
[21]
plasma ovarian cancer (38) -- 178 (12–3468) [22]
serum ovarian cancer, post-surgery (267)
healthy controls (67)
74 ± 116
147 ± 192
25 (25–671)
85 (25–617)
[23]
heparin plasma non-small lung cancer (158)
benign pulmonary disease (54)
healthy controls (25)
356.2
175.6
29.5
319.1 (16–1600)
161.6 (1.3–442.8)
17.9 (0–102.8)
[24]
EDTA plasma coronary artery disease (107)
healthy controls (71)
616 ± 308
443 ± 237
--
--
[16]
EDTA plasma interstitial pneumonia (17)
healthy controls (20)
945 ± 256
156.7 ± 52.2
--
--
[15]BMC Cancer 2006, 6:207 http://www.biomedcentral.com/1471-2407/6/207
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regardless of the type of assay used. For any multi-center
investigation involving the measurement of plasma OPN,
the collection and storage of plasma should be strictly reg-
ulated and the ELISA analysis should be centralized.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DV designed the study, performed statistical analysis and
drafted the manuscript.
HMS analyzed plasma samples and reviewed the manu-
script.
AK analyzed plasma samples and reviewed the manu-
script.
TK treated the patients, collected plasma samples and
reviewed the manuscript.
GH treated the patients, collected plasma samples and
reviewed the manuscript.
JD treated the patients, collected plasma samples and
reviewed the manuscript.
MF performed statistical analysis and reviewed the manu-
script.
MB designed the study, collected plasma samples, per-
formed statistical analysis and drafted the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported in part by the Deutsche Forschungsgemeinschaft 
(to DV).
References
1. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B,
Pinto HA, Koong AC, Giaccia AJ: Identification of osteopontin as
a prognostic plasma marker for head and neck squamous
cell carcinomas.  Clin Cancer Res 2003, 9:59-67.
2. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Dan-
ish Head and Neck Cancer Study Group: Plasma osteopontin,
hypoxia, and response to the hypoxia sensitiser nimorazole
in radiotherapy of head and neck cancer: results from the
DAHANCA 5 randomised double-blind placebo-controlled
trial.  Lancet Oncol 2005, 6:757-764.
3. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen
G: Anemia in cervical cancers: impact on survival, patterns of
relapse, and association with hypoxia and angiogenesis.  Int J
Radiat Oncol Biol Phys 2003, 56:778-787.
4. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill
RP: Tumor hypoxia has independent predictor impact only in
patients with node-negative cervix cancer.  J Clin Oncol 2002,
20:680-687.
5. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M,
Webb C, Wali A: Asbestos exposure, pleural mesothelioma,
and serum osteopontin levels.  N Engl J Med 2005,
353:1564-1573.
6. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, Hors-
man MR: Influence of oxygen concentration and pH on
expression of hypoxia induced genes.  Radiother Oncol 2005,
76:187-193.
7. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le
QT: Hypoxia upregulates osteopontin expression in NIH-3T3
cells via a Ras-activated enhancer.  Oncogene 2005,
24:6555-6563.
8. Lukacova S, Khalil AA, Overgaard J, Alsner J, Horsman MR: Relation-
ship between radiobiological hypoxia in a C3H mouse mam-
mary carcinoma and osteopontin levels in mouse serum.  Int
J Radiat Biol 2006, 81:937-944.
9. Said HM, Katzer A, Flentje M, Vordermark D: Response of the
plasma hypoxia marker osteopontin to in vitro hypoxia in
human tumor cells.  Radiother Oncol 2005, 76:200-205.
10. Rittling SR, Chambers AF: Role of osteopontin in tumor pro-
gression.  Brit J Cancer 2004, 90:1877-1881.
11. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P,
Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J: Prog-
nostic value of tumor oxygenation in 397 head and neck
tumors after primary radiation therapy. An international
multi-center study.  Radiother Oncol 2005, 77:18-24.
12. Denhardt DT, Guo X: Osteopontin: a protein with diverse func-
tions.  FASEB J 1993, 7:1475-1482.
13. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, Tan-
aka K, Rashid MM, Inobe M, Chambers AF, Uede T: Antibodies to
different peptides in osteopontin reveal complexities in the
various secreted forms.  J Cell Biochem 2000, 77:487-498.
14. Arai M, Yokosuka O, Kanda T, Fukai K, Imazeki F, Murumatsu M, Seki
N, Miyazaki M, Ochiai T, Hirasawa H, Saisho H: Serum osteopontin
levels in patients with acute liver dysfunction.  Scand J Gastro-
enterol 2006, 41:102-110.
15. Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K,
Koguchi Y, Fukushima K, Kon S, Kohno S, Saito A, Uede T, Nasu M:
High plasma concentrations of osteopontin in patients with
interstitial pneumonia.  Respir Med 2005, 99:111-117.
16. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M,
Nakamura H, Ohsuzu F: Plasma osteopontin levels are associ-
ated with the presence and extent of coronary artery dis-
ease.  Atherosclerosis 2003, 170:333-337.
17. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L: Ele-
vated osteopontin levels in active relapsing-remitting multi-
ple sclerosis.  Ann Neurol 2003, 53:819-822.
18. Wong TS, Kwong DL, Sham J, Wei WI, Kwong YL, Yuen AP: Eleva-
tion of plasma osteopontin level in patients with undifferen-
tiated nasopharyngeal carcinoma.  Eur J Surg Oncol 2005,
31:555-558.
19. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L,
Bray-Ward P, Ward DC: Serum protein markers for early
detection of ovarian cancer.  Proc Natl Acad Sci USA 2005,
102:7677-7682.
20. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue
H, Kondo M, Mori Y, Tanaka E, Imamura M: Clinical significance of
osteopontin in esophageal squamous cell carcinoma: com-
parison with common tumor markers.  Oncol 2005, 68:285-92.
21. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM,
Berkowitz RS, Cramer DW, Mok SC: Osteopontin as a potential
diagnostic biomarker for ovarian cancer.  JAMA 2002,
287:1671-1679.
22. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim
JH, Cramer DW, Berkowitz RS, Mok SC: Osteopontin as an
adjunct to CA125 in detecting recurrent ovarian cancer.  Clin
Cancer Res 2004, 10:3474-3478.
23. Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, Seiden
MV: Utility of osteopontin as a biomarker in recurrent epi-
thelial ovarian cancer.  Gynecol Oncol 2004, 93:361-365.
24. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han M, MA Y, Di X,
Gao M, Ma J, Zhang J, Cheng S, Gao Y: Overexpression of oste-
opontin is associated with more aggressive phenotypes in
human non-small cell lung cancer.  Clin Cancer Res 2005,
11:4646-4652.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:207 http://www.biomedcentral.com/1471-2407/6/207
Page 6 of 6
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/207/pre
pub